OVERVIEW

The Future of Early-Stage NSCLC Treatment: Updates on Neoadjuvant Immunotherapy is organized by Paradigm Medical Communications, LLC.

Release Date: November 30, 2021
Last Reviewed: November 22, 2021
Expiration Date: November 30, 2022

Target Audience:
This activity has been designed to address the educational needs of medical oncologists. It may also be of benefit to other healthcare professionals who manage patients with non-small cell lung cancer (NSCLC).

Overview:
Approximately half of all patients with early-stage NSCLC relapse after treatment with curative intent, which typically includes surgery, radiation, and adjuvant systemic therapy. The success of immune checkpoint inhibitor (ICI) treatment of advanced NSCLC, and the biologic rationale for a more intact locoregional immune system, has resulted in multiple ongoing clinical trials for neoadjuvant ICI therapy. Early data have been released from some of these trials, showing promising results that indicate the treatment paradigm for early-stage NSCLC may be poised for a major shift. Although this is exciting, there are unanswered questions that can only be addressed by clinical trial results, leading to a critical need for education about the potential future of neoadjuvant therapy for early-stage NSCLC, including the latest data from ongoing neoadjuvant ICI clinical trials.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Summarize the latest clinical trial data on neoadjuvant immunotherapy-based regimens for the treatment of early-stage NSCLC
• Describe potential adverse events that have been associated with neoadjuvant immunotherapy regimens being evaluated for the treatment of early-stage NSCLC